Carasent Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Daniel Ohman

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2yrs
Participación del CEO	0.2%
Permanencia media de la dirección	2yrs
Promedio de permanencia en la Junta Directiva	2.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Daniel Ohman (44 yo)

2yrs

Permanencia

Mr. Daniel Ohman was the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager of VG...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Svein Bjornstad	Chief Financial Officer	3.3yrs	sin datos	0.49% € 577.3k
Daniel Ohman	Chief Executive Officer	2yrs	sin datos	0.22% € 263.0k
Johan Eltes	Chief Technical Officer	2.1yrs	sin datos	sin datos
Jon Schultz	Legal Counsel	no data	NOK 45.00k	sin datos
Stefan Jernberg	Chief Compliance Officer	less than a year	sin datos	sin datos
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 723.00k	sin datos
Cornelia Broqvist	Chief Marketing Officer	2.2yrs	sin datos	sin datos
Anna Larsson	People and Culture Manager	no data	sin datos	sin datos
Vilma Jonson	Head of Strategy	1.2yrs	sin datos	0.033% € 39.4k

2.0yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de C34 se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tomas Meerits	Director	1.5yrs	sin datos	sin datos
Camilla Skoog	Independent Director	2.6yrs	sin datos	0.013% € 15.3k
Ulrika Sundling	Independent Director	2.6yrs	sin datos	0.028% € 32.6k
Petri Niemi	Independent Chairman of the Board	2.1yrs	sin datos	0.017% € 20.0k
Henric Carlsson	Independent Director	less than a year	sin datos	sin datos

2.1yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de C34 no se considera experimentada (2.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Carasent Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Chief Executive Officer recently bought €121k worth of stock

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad